{"nctId":"NCT00131664","briefTitle":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","startDateStruct":{"date":"2005-09"},"conditions":["Type 2 Diabetes Mellitus"],"count":391,"armGroups":[{"label":"Avandamet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Avandamet"]},{"label":"Avandia and Amaryl","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Avandia and Amaryl"]},{"label":"Metformin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]}],"interventions":[{"name":"Avandamet","otherNames":["rosiglitazone maleate and metformin hydrochloride","Avandamet 2 mg / 500 mg","Avandamet 4 mg / 500 mg","Avandamet 4 mg / 1000 mg"]},{"name":"Avandia and Amaryl","otherNames":["rosiglitazone maleate and glimepiride","Avandia (rosiglitazone maleate) 4 mg","Avandia (rosiglitazone maleate) 8 mg","Amaryl (glimepiride) 1 mg","Amaryl (glimepiride) 2 mg","Amaryl (glimepiride) 4 mg"]},{"name":"Metformin","otherNames":["Metformin 500 mg","Metformin 850 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Type 2 diabetes patients\n2. 18 - 75 years old\n3. Type 2 diabetes mellitus (DM) drug naïve or on submaximal oral monotherapy \\< 3 years\n4. A1C criteria at screening:\n\n   1. 7.1-10% for drug naïve patients after failure of diet control and life-style modification\n   2. 7.1 - 9% on single therapy (e.g. not more 10 mg of Glyburide or 4 mg of Amaryl™ or 1000mg of Metformin) who will start after 2 weeks wash-out. During wash out the following will be done: i) diet and life style modification ii) Angiotensin converting enzyme inhibitor (ACE), aspirin (80 mg), and statin if appropriate\n5. Signed informed consent\n\nExclusion Criteria:\n\n1. Type 1 diabetes\n2. Subjects currently treated with insulin\n3. Subject treated for previous 3 month with any thiazolidinedione (TZD)\n4. Evidence of clinically significant concomitant illnesses which are not controlled by medication and/or may limit participation in the study as judged by the investigator\n5. Subjects who have hypersensitivity to any components of study drugs\n6. Participation in a clinical trial and/or intake of an investigational drug within 30 days prior to screening.\n7. Pregnant or nursing females\n8. Females of childbearing potential who are not on adequate birth control\n9. Liver enzymes (Alanine Aminotransferase (ALT) \\> 2.5 times upper limit of normal)\n10. Renal impairment: serum creatinine ≥ 136umol/L (males) and ≥ 124 umol/L (females)\n11. Congestive Heart Failure (CHF class III/IV)\n12. Weight \\>160 kg","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in A1C at Month 6","description":"Change from baseline was calculated as the Month 6 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":"0.095"},{"groupId":"OG001","value":"7.96","spread":"0.076"},{"groupId":"OG002","value":"7.90","spread":"0.085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.61","spread":"0.108"},{"groupId":"OG001","value":"-1.39","spread":"0.081"},{"groupId":"OG002","value":"-1.02","spread":"0.092"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in A1C at Month 4","description":"Change from baseline was calculated as the Month 4 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"0.099"},{"groupId":"OG001","value":"-1.28","spread":"0.083"},{"groupId":"OG002","value":"-0.94","spread":"0.097"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in A1C at Month 12","description":"Change from baseline was calculated as the Month 12 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.50","spread":"0.115"},{"groupId":"OG001","value":"-1.56","spread":"0.086"},{"groupId":"OG002","value":"-1.14","spread":"0.111"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving A1C Target at Month 4","description":"A1C responders were described as subjects having achieved A1C less than 7 percent at Month 4, with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"96","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving A1C Target at Month 6","description":"A1C responders were described as subjects having achieved A1C less than 7 percent at Month 6, with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving A1C Target at Month 12","description":"A1C responders were described as subjects having achieved A1C less than 7 percent at Month 12 with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"111","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 4","description":"Change from baseline was calculated as the Month 4 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.86","spread":"0.247"},{"groupId":"OG001","value":"-2.33","spread":"0.181"},{"groupId":"OG002","value":"-1.75","spread":"0.204"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 6","description":"Change from baseline was calculated as the Month 6 value minus the baseline value, with last on-treatment observation carried forward (LOCF) from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.98","spread":"0.259"},{"groupId":"OG001","value":"-2.55","spread":"0.200"},{"groupId":"OG002","value":"-1.86","spread":"0.192"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Month 12","description":"Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 2 for withdrawn subjects or missing values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.71","spread":"0.274"},{"groupId":"OG001","value":"-2.76","spread":"0.225"},{"groupId":"OG002","value":"-2.12","spread":"0.231"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving FPG Target at Month 4","description":"FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 4 with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving FPG Target at Month 6","description":"FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 6 with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving FPG Target at Month 12","description":"FPG responders were described as subjects having achieved FPG less than 7 mmol/L at Month 12 with LOCF from Month 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 6","description":"Change from baseline was calculated as the Month 6 value minus the baseline value, with LOCF from Month 2. The UKPDS (United Kingdom Prospective Diabetes Study) risk engine calculated was based on 5 years risk using gender, race, age at diagnosis of diabetes, duration of diabetes, smoking status, A1C, systolic blood pressure and total cholesterol to high-density lipoprotein (HDL) ratio at a specified visit.\n\nThe UKPDS cardiovascular disease (CVD) risk engine is used to estimate the risk of having coronary heart disease in type II diabetes according to the UKPDS model. The possible risk scores can range from 0 to 100% and hence lower scores would predict a person is less likely to have an event.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.09","spread":"0.246"},{"groupId":"OG001","value":"-1.05","spread":"0.169"},{"groupId":"OG002","value":"-1.54","spread":"0.234"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in 5 Year UKPDS Risk Scores at Month 12","description":"Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 2. The UKPDS (U.K. Prospective Diabetes Study) risk engine calculated was based on 5 years risk using gender, race, age at diagnosis of diabetes, duration of diabetes, smoking status, A1C, systolic blood pressure and total cholesterol to HDL ratio at a specified visit.\n\nThe UKPDS cardiovascular disease (CVD) risk engine is used to estimate the risk of having coronary heart disease in type II diabetes according to the UKPDS model. The possible risk scores can range from 0 to 100% and hence lower scores would predict a person is less likely to have an event.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.72","spread":"0.392"},{"groupId":"OG001","value":"-0.62","spread":"0.252"},{"groupId":"OG002","value":"-1.11","spread":"0.234"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-reactive Protein (CRP) at Month 6","description":"Change from baseline was calculated as the Month 6 value minus the baseline value. LOCF was not used for this analysis. CRP was only done at baseline, months 6 and 8. The test was optional and performed only by participating sites.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.419"},{"groupId":"OG001","value":"-1.68","spread":"0.640"},{"groupId":"OG002","value":"-1.25","spread":"0.804"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in C-reactive Protein (CRP) at Month 12","description":"Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 6. CRP was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.40","spread":"0.323"},{"groupId":"OG001","value":"-1.52","spread":"0.642"},{"groupId":"OG002","value":"-1.52","spread":"0.817"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Adiponectin at Month 6","description":"Change from baseline was calculated as the Month 6 value minus the baseline value. LOCF was not used for this analysis. Adiponectin was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":"0.869"},{"groupId":"OG001","value":"6.37","spread":"1.453"},{"groupId":"OG002","value":"0.23","spread":"0.299"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Adiponectin at Month 12","description":"Change from baseline was calculated as the Month 12 value minus the baseline value, with LOCF from Month 6. Adiponectin was only done at baseline, months 6 and 12. The test was optional and performed only by participating sites.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.95","spread":"0.902"},{"groupId":"OG001","value":"8.21","spread":"1.804"},{"groupId":"OG002","value":"1.453","spread":"0.371"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":136},"commonTop":["Fracture"]}}}